ApoE4 blood marker assay

Why ApoE4?

Apolipoprotein E is a glycoprotein involved in lipid metabolism. It is encoded by the APOE gene, which has three different alleles (ε2, ε3 and ε4) that encode three different ApoE isoforms (ApoE2, ApoE3 and ApoE4, respectively). To date only the presence of one or two APOE ε4 alleles is accepted as a reliable biomarker and risk factor for late-onset AD4, 6. The risk of developing AD is increased by 3–5 fold in the presence of one ε4 allele, and by 15–20 fold in case of homozygosity5. ApoE4 carriers thus clearly constitute a target population for research, clinical trials, and the development of preventive strategies.

The failure of putative AD treatments in the last decade led to a change in corresponding research and health strategies, with significantly more effort and investment now focused on the development of strategies to delay or prevent AD, and to identify at-risk individuals before disease onset.

The identification of ApoE4 carriers would allow:
-Institution of preventive lifestyle-based interventions that could prevent or delay the development of the disease, and could in turn entail significant savings for healthcare systems. For example, it has been estimated that a 10% reduction in cardiovascular disease incidence would equate to a 10% saving in medical costs attributable to AD and related dementias3.

-Enrichment of clinical trials with ApoE4 carriers, a population of significant informative value from an epidemiological perspective. This biomarker is currently being used for patient stratification in the latest clinical trials evaluating experimental treatments for AD 1,2

-Administration of treatments during the earliest stages of the disease. Early identification of ApoE4 carriers would allow regular monitoring of this at-risk population and facilitate treatment administration once the first symptoms develop, thus maximizing neural tissue preservation.

The identification of ApoE4 carriers would allow:
-Institution of preventive lifestyle-based interventions that could prevent or delay the development of the disease, and could in turn entail significant savings for healthcare systems. For example, it has been estimated that a 10% reduction in cardiovascular disease incidence would equate to a 10% saving in medical costs attributable to AD and related dementias3.

-Enrichment of clinical trials with ApoE4 carriers, a population of significant informative value from an epidemiological perspective. This biomarker is currently being used for patient stratification in the latest clinical trials evaluating experimental treatments for AD 1,2

-Administration of treatments during the earliest stages of the disease. Early identification of ApoE4 carriers would allow regular monitoring of this at-risk population and facilitate treatment administration once the first symptoms develop, thus maximizing neural tissue preservation.

If you have any questions or comments,  we will be pleased to attend you

If you have any questions or comments,  
we will be pleased to attend you

Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain

+34 983 54 98 96